Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Molecular Testing for Alveolar Soft-Part Sarcoma

Last updated March 3, 2017

Molecular Testing for Alveolar Soft-Part Sarcoma is a genetic test that is helpful in aiding a diagnosis of alveolar soft-part sarcoma.

What are other Names for this Test? (Equivalent Terms)

  • Gene Mutation Analysis for Alveolar Soft-Part Sarcoma
  • Molecular Testing for ASPS
  • Test for Molecular Diagnosis of Alveolar Soft-Part Sarcoma

What is Molecular Testing for Alveolar Soft-Part Sarcoma? (Background Information)

  • Molecular Testing for Alveolar Soft-Part Sarcoma is a genetic test that is helpful in aiding a diagnosis of alveolar soft-part sarcoma. The lab test results may also be subsequently useful in taking appropriate treatment decisions
  • Alveolar soft-part sarcoma (ASPS) is an extremely infrequent, but highly malignant tumor of the soft tissues and muscles. It is formed due to chromosomal aberrations causing abnormal fused genes. This abnormal gene forms a certain kind of protein that is responsible for the tumor formation
  • Young individuals are most prone to ASPS. Most of these tumors are well-defined and form deep within the body tissues, including in the muscles, nerves, and bones. The most common location for this tumor is the thigh, leg, and buttock

The cause of alveolar soft-part sarcoma is due to genetic mutations. Currently, studies indicate defects in the following genes:

  • ASPSCR1-TFE3 causing chromosomal abnormality namely der(17)t(X;17)(p11;q25)

The above genetic abnormality can be detected using molecular studies, which may play a significant role in identifying the tumor type, and in some cases, helping the healthcare provider take appropriate treatment decisions.

The molecular testing, in general, can be performed using a variety of methods. Some of these methods include:

  • In situ hybridization technique, such as fluorescence in situ hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Next-generation sequencing (NGS)
  • Polymerase chain reaction (PCR)
  • Comparative genomic hybridization (CGH)
  • Karyotyping including spectral karyotyping
  • mRNA analysis
  • Tissue microarrays (TMAs)
  • Southern blot test
  • Northern blot test
  • Western blot test
  • Eastern blot test

The methodology used for alveolar soft-part sarcoma may vary from one laboratory to another. 

Note: Molecular testing has limitations due to the molecular method and genetic mutational abnormalities being tested. This can affect the results on a case-by-case basis. Consultation with your healthcare provider will help in determining the right test and right molecular method, based on individual circumstances.

What are the Clinical Indications for performing the Molecular Testing for Alveolar Soft-Part Sarcoma Test?

Molecular Testing for Alveolar Soft-Part Sarcoma is undertaken in the following situations: 

  • To assist (and in some cases, confirm) the initial diagnosis of alveolar soft-part sarcoma
  • To distinguish other tumors/conditions that have similar histological features, when examined by a pathologist under the microscope
  • To help in determining treatment options
  • To confirm recurrence of the tumor: Tumor recurrence can either be at the original tumor site, or at a distant location (away from the initial site)

How is the Specimen Collected for Molecular Testing for Alveolar Soft-Part Sarcoma?

Following is the specimen collection process for Molecular Testing for Alveolar Soft-Part Sarcoma:

The specimen sample requirements may vary from lab to lab. Hence, it is important to contact the testing lab for exact specimen requirements, before initiating the testing process.

  • Sample required:
    • Fresh tumor tissue during biopsy
    • Formalin-fixed paraffin-embedded solid tumor tissue (FFPE tumor tissue), often referred to as paraffin block of the tumor
    • Unstained tissue slides
  • Process of obtaining the sample: As outlined by the laboratory testing facility
  • Preparation required: As outlined by the laboratory testing facility


  • Depending on the location of testing, it may take up to 2 weeks’ turnaround time, to obtain the test results
  • Occasionally, additional samples may be required to either repeat the test or to perform follow-up testing
  • Many hospitals preserve the paraffin blocks for at least 7 years. In general, older paraffin blocks (over 5 years) may affect the detection of specific mutations, due to degradation of the tumor specimen over time

Cost of Molecular Testing for Alveolar Soft-Part Sarcoma:

  • The cost of the test procedure depends on a variety of factors, such as the type of your health insurance, annual deductibles, co-pay requirements, out-of-network and in-network of your healthcare providers and healthcare facilities
  • In many cases, an estimate may be provided before the test is conducted. The final amount may depend upon the findings during the test procedure and post-operative care that is necessary (if any)

What is the Significance of the Molecular Testing for Alveolar Soft-Part Sarcoma Result?

The significance of Molecular Testing for Alveolar Soft-Part Sarcoma is explained:

  • Presence of a positive test result helps aid, and in some cases, confirm the diagnosis of alveolar soft-part sarcoma
  • The result can help exclude other tumors with similar histological features
  • It can help determine the prognosis of the patient
  • In some cases, the test results may help in taking treatment decisions

The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.

Additional and Relevant Useful Information:

  • Many laboratories may not have the capability to perform this test. Only highly-specialized labs with advanced facilities and testing procedures may perform this test
  • Additional mutations are still being discovered in many of these tumors. This may further contribute towards tumor diagnosis and treatment. Please consult with your healthcare provider for any information updates

Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.

What are some Useful Resources for Additional Information?

The following DoveMed website link is a useful resource for additional information:


Please visit our Laboratory Procedures Center for more physician-approved health information:


References and Information Sources used for the Article:

https://ghr.nlm.nih.gov/primer/testing/genetictesting (accessed on 02/17/2017)

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5806a1.htm (accessed on 02/17/2017)

http://www.nature.com/gim/journal/v10/n5/full/gim200852a.html (accessed on 02/17/2017)

http://pediatrics.aappublications.org/content/106/6/1494 (accessed on 02/17/2017)

http://atlasgeneticsoncology.org/Tumors/AlveolSoftPartSID5125.html (accessed on 02/17/2017)

https://www.ncbi.nlm.nih.gov/pubmed/12769020 (accessed on 02/17/2017)

http://www.archivesofpathology.org/doi/pdf/10.1043/1543-2165(2007)131%5B488%3AASPS%5D2.0.CO%3B2?code=coap-site (accessed on 02/17/2017)

Helpful Peer-Reviewed Medical Articles:

Carrano, A. V., et al. Measurement and purification of human chromosomes by flow cytometry and sorting. Proceedings of the National Academy of Sciences 76, 1382–1384 (1979)

Drets, M. E., & Shaw, M. W. Specific banding patterns of human chromosomes. Proceedings of the National Academy of Sciences 68, 2073–2077 (1971)

Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002)

Parra, I., & Windle, B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genetics 5, 17–21 (1993) doi:10.1038/ng0993-17

Pinkel, D., et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 20, 207–211 (1998) doi:10.1038/2524

Speicher, M. R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genetics 12, 368–375 (1996) doi:10.1038/ng0496-368

Gambarotti, M. (2014). Alveolar Soft Part Sarcoma. In Atlas of Musculoskeletal Tumors and Tumorlike Lesions (pp. 365-368). Springer International Publishing.

Brennan, M. F., Antonescu, C. R., Alektiar, K. M., & Maki, R. G. (2016). Alveolar Soft Part Sarcoma. In Management of Soft Tissue Sarcoma (pp. 283-289). Springer International Publishing.

Jaber, O. I., & Kirby, P. A. (2015). Alveolar soft part sarcoma. Archives of pathology & laboratory medicine, 139(11), 1459-1462.

Kummar, S., Allen, D., Monks, A., Polley, E. C., Hose, C. D., Ivy, S. P., ... & Simon, R. (2013). Cediranib for metastatic alveolar soft part sarcoma. Journal of Clinical Oncology, 31(18), 2296-2302.

Pennacchioli, E., Fiore, M., Collini, P., Radaelli, S., Dileo, P., Stacchiotti, S., ... & Gronchi, A. (2010). Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Annals of surgical oncology, 17(12), 3229-3233.

Williams, A., Bartle, G., Sumathi, V. P., Meis, J. M., Mangham, D. C., Grimer, R. J., & Kindblom, L. G. (2011). Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features. Virchows Archiv, 458(3), 291-300.

Rekhi, B., Ingle, A., Agarwal, M., Puri, A., Laskar, S., & Jambhekar, N. A. (2012). Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology, 44(1), 11-17.

Tsuji, K., Ishikawa, Y., & Imamura, T. (2012). Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. Human pathology, 43(3), 356-363.

Hodge, J. C., Pearce, K. E., Wang, X., Wiktor, A. E., Oliveira, A. M., & Greipp, P. T. (2014). Molecular cytogenetic analysis for TFE3 rearrangement in Xp11. 2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Modern Pathology, 27(1), 113-127.

Orbach, D., Brennan, B., Casanova, M., Bergeron, C., Mosseri, V., Francotte, N., ... & Ferrari, A. (2013). Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatric blood & cancer, 60(11), 1826-1832.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: March 3, 2017
Last updated: March 3, 2017